? CORE A The Administrative and Biostatistics Core (referred to as Core A). Core A has two interrelated components: Administrative and Biostatistics, which serve to advance the missions of the P01 that are not able to be served by other entities. The overriding objectives or Specific Aims of the Administrative component, under the direction of Dr. Anil Rustgi (also overall Director of Core A), is to coordinate an integrated research program between the Projects and with strong support from the scientific Cores. This Administrative component also facilitates interactions with Penn's Perelman's School of Medicine, its NCI designated Abramson Cancer Center, external institutions, enrichment programs, career development pathways, catalyzes new directions for our P01, and ensures that the P01 has the unequivocal and wholehearted institutional support. The Biostatistics component, under the direction of Dr. Qi Long, Professor of Biostatistics, is located in the Penn Center for Clinical Epidemiology and Biostatistics (CCEB). Its objectives or Specific Aims are to provide comprehensive support for the Projects in experimental design, statistical modeling/analysis, data interpretation and methodological investigations. In aggregate, this Core enables innovative basic science research with translation of robust preclinical models into new perspectives in therapeutics of esophageal cancer, which is a major gap in the field.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA098101-18
Application #
9912112
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Campbell, Joshua D; Yau, Christina; Bowlby, Reanne et al. (2018) Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23:194-212.e6
Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478
Giroux, VĂ©ronique; Stephan, Julien; Chatterji, Priya et al. (2018) Mouse Intestinal Krt15+ Crypt Cells Are Radio-Resistant and Tumor Initiating. Stem Cell Reports 10:1947-1958
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167
Bockorny, Bruno; Rusan, Maria; Chen, Wankun et al. (2018) RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Mol Cancer Ther 17:1526-1539
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Karakasheva, Tatiana A; Dominguez, George A; Hashimoto, Ayumi et al. (2018) CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 3:

Showing the most recent 10 out of 173 publications